Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMAW), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
The Dermata Therapeutics, Inc. (DRMA, DRMAW) news page on Stock Titan aggregates company-issued updates, clinical milestones, financing announcements, and regulatory disclosures related to its dermatology-focused business. Dermata describes itself as a science-driven leader in dermatologic solutions built around its proprietary Spongilla technology platform, with programs in acne, hyperhidrosis, and other skin diseases and aesthetic applications.
Recent news highlights Dermata’s strategic pivot from prescription dermatology development to over-the-counter (OTC) pharmaceutical skin treatments that can be sold directly to consumers. Company press releases and an accompanying Form 8-K explain that Dermata is prioritizing an OTC once-weekly acne kit that combines an active ingredient from the OTC acne monograph with its Spongilla technology, with launch preparations involving branding, packaging, manufacturing, and consumer research.
News items also cover clinical and scientific developments, such as positive topline data from the Phase 3 STAR-1 trial of XYNGARI™ in moderate-to-severe acne, additional data presentations at international dermatology congresses, and collaboration activities around DMT410 for topical botulinum toxin delivery in hyperhidrosis and aesthetic indications. Financing-related releases describe private placements and warrant transactions intended to fund operations and OTC product launch activities, while other notices address Nasdaq listing compliance and corporate actions like a reverse stock split.
Investors and observers can use this news feed to follow Dermata’s progress in OTC dermatology, updates on its Spongilla-based acne kit, developments in its DMT410 program, intellectual property milestones, and material events reported in 8-K filings. Bookmark this page to review Dermata’s historical and ongoing disclosures as it advances its dermatology strategy.
Dermata (NASDAQ:DRMA) announced the Australian Patent Office granted Australian Patent No. 2019419387 for its Spongilla technology combination as a method to treat acne on January 20, 2026. This follows an already-issued U.S. patent covering the same technology. Dermata plans to launch a once-weekly, over-the-counter acne treatment system incorporating Spongilla in mid-2026 in the U.S. The company said the granted patent strengthens its global intellectual property estate, with additional patent filings pending in other jurisdictions and Australia cited as a key future market.
Dermata Therapeutics (Nasdaq:DRMA / DRMAW) closed a private placement priced at-the-market, issuing 2,022,062 shares (or pre-funded warrants) and accompanying series C and series D warrants at $2.04 per share (or pre-funded warrant).
Gross proceeds were approximately $4.1 million upfront, with up to $8.3 million of additional gross proceeds possible if warrants are fully exercised. Series C warrants expire five years after stockholder approval; series D warrants expire 24 months after approval. The company amended prior warrants covering 120,734 shares, lowering the exercise price to $2.04. Insiders participated; H.C. Wainwright acted as placement agent. Proceeds are planned for general corporate purposes and product launch activities.
Dermata Therapeutics (NASDAQ:DRMA / DRMAW) announced a private placement to issue 2,022,062 shares (or pre-funded warrants) plus series C and short-term series D warrants at $2.04 per share, providing approximately $4.1 million of gross proceeds upfront and up to ~$8.3 million additional if warrants are fully exercised (total ~$12.4 million). Series C warrants expire five years; series D warrants expire 24 months; warrant exercises and amended warrants are subject to stockholder approval. Closing expected on or about December 29, 2025. Company insiders, including the CEO and CFO, are participating. H.C. Wainwright is placement agent. Net proceeds for general corporate purposes and OTC acne kit activities.
Dermata Therapeutics (NASDAQ:DRMA) announced it will unveil a new brand identity for its over-the-counter skincare business in the coming weeks, positioning the unit as a "science-first" consumer skincare brand that blends ancestral remedies with clinical innovation. The company said the identity reflects a mission to deliver potent, health-forward products and will frame therapies and technologies through quantifiable performance.
Dermata plans to launch its first OTC once-weekly acne kit in mid-2026 and will release visual assets, product positioning, and phased launch communications over the coming months.
Dermata Therapeutics (Nasdaq: DRMA) announced a strategic pivot to develop and commercialize over-the-counter dermatology products and reported Q3 2025 results. The company plans to launch a once-weekly acne kit using its Spongilla technology in mid-2026 and is developing branding, packaging, and manufacturing for direct-to-consumer and professional sales.
Recent clinical progress includes positive topline Phase 3 STAR-1 results that met all three primary endpoints and showed separation from placebo by week 4. As of September 30, 2025, Dermata had $4.7 million in cash and expects funding into Q2 2026.
Dermata Therapeutics (NASDAQ:DRMA) announced the acceptance of its patent application by the Australian Patent Office for its Spongilla technology combination to treat acne. The patent, which follows a similar U.S. patent issuance, will automatically be granted in mid-January 2026 unless opposed.
The company plans to launch a once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit incorporating its Spongilla technology by mid-2026. This innovative treatment targets underlying acne mechanisms with enhanced precision, potentially offering improved outcomes and reduced side effects. The Australian market represents a significant opportunity with over 3.3 million people diagnosed with acne.
Dermata Therapeutics (NASDAQ:DRMA) announced the upcoming presentation of an abstract from its Phase 3 STAR-1 clinical trial of XYNGARI™ (DMT310) at the European Academy of Dermatology and Venereology Congress 2025 in Paris, France.
The abstract, titled "Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris," will be released on September 16, 2025. The presentation will highlight additional primary and secondary data from the Phase 3 study evaluating XYNGARI™ for moderate-to-severe acne treatment.
Dermata Therapeutics (Nasdaq:DRMA) announced a strategic pivot from prescription medications to over-the-counter (OTC) skin care treatments. This decision follows the successful Phase 3 STAR-1 clinical trial of XYNGARI™, their once-weekly topical acne treatment using proprietary Spongilla technology.
The company plans to launch its first OTC acne kit by mid-2026, targeting nearly 50 million US acne patients. The product will combine an FDA-approved OTC monograph active ingredient with their Spongilla technology. This strategic shift aims to accelerate commercialization, reduce regulatory burden, and broaden customer access by eliminating insurance coverage limitations.
As part of this transition, Dermata has withdrawn its investigational new drug application for XYNGARI™ with the FDA to gain more flexibility in leveraging its Spongilla technology for various OTC skin care products.
Dermata Therapeutics (NASDAQ:DRMA) reported significant progress in Q2 2025, highlighted by positive Phase 3 STAR-1 trial results for XYNGARI™ in treating moderate-to-severe acne. The trial achieved statistically significant results for all three co-primary endpoints at both 4 and 12 weeks versus placebo.
The company strengthened its financial position by raising $8.8 million in gross proceeds through private placement and warrant inducement financings in H1 2025. As of June 30, 2025, Dermata had $6.5 million in cash, expected to fund operations into Q2 2026. Q2 R&D expenses decreased to $0.6 million from $2.0 million year-over-year, while G&A expenses increased to $1.2 million from $0.9 million.
Dermata Therapeutics (NASDAQ:DRMA) has received a patent grant from the Australian Patent Office for its DMT410 program, which uses Spongilla technology to topically deliver botulinum toxin for treating hyperhidrosis. This marks the company's second granted patent for DMT410.
The patent, titled "Compositions for the treatment of skin conditions" (No. 2109284621), strengthens Dermata's global intellectual property portfolio. The company has recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 specifically for axillary hyperhidrosis treatment, with potential applications for palmer and plantar hyperhidrosis.
FAQ
What is the current stock price of Dermata Therapeutics (DRMAW)?
